Such genetic changes can be seen in EBV-negative BL having a higher frequency of mutations that interfere with apoptosis (TP53 and USP7) and mutations in TCF3 and ID3 enhance B cell receptor signaling [52]. The gene discussed is TP53; the disease is Burkitt lymphoma.